{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:14:08Z","timestamp":1715991248401},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,4,7]],"date-time":"2008-04-07T00:00:00Z","timestamp":1207526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There is limited comparative data between efavirenz (EFV) 600\u2003mg\/day and nevirapine (NVP) 400\u2003mg\/day\u2010based antiretroviral therapy (ART) among HIV\u20101 patients with tuberculosis (TB) and receiving rifampicin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study was conducted in all ART\u2010na\u00efve patients who were receiving rifampicin between January 2002 and December 2005.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 188 patients, 77 and 111 patients were initiated on EFV\u2010based ART (EFV group) and NVP\u2010based ART (NVP group), respectively. Overall, median [interquartile range (IQR)] CD4 count was 36 (15\u201377) cells\/\u03bcL and median (IQR) viral load was 5.6 (5.2\u20135.9) HIV\u20101 RNA log copies\/mL. At 48 weeks, 77.9% (60\/77) in the EFV group and 67.6% (75\/111) in the NVP group achieved HIV\u20101 RNA &lt;50\u2003copies\/mL (<jats:italic>P<\/jats:italic>=0.140, odds ratio =0.590, 95% confidence interval=0.302\u20131.153). At 24 and 48 weeks, respective median CD4 counts were 174 and 254\u2003cells\/\u03bcL in the EFV group and 156 and 218\u2003cells\/\u03bcL in the NVP group (<jats:italic>P<\/jats:italic>&gt;0.05). By binary logistic regression, treatment group was not associated with HIV\u20101 RNA &lt;50\u2003copies\/mL (<jats:italic>P<\/jats:italic>&gt;0.05). No patient in the EFV group and eight (7.2%) patients in the NVP group discontinued ART because of adverse reactions (<jats:italic>P<\/jats:italic>=0.084).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For HIV\u2013TB co\u2010infected patients who receive rifampicin, efficacy of 600\u2003mg EFV\u2010based and 400\u2003mg NVP\u2010based ART may be similar, although adverse events tend to be higher in NVP\u2010based ART.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00563.x","type":"journal-article","created":{"date-parts":[[2008,4,7]],"date-time":"2008-04-07T18:27:42Z","timestamp":1207592862000},"page":"294-299","source":"Crossref","is-referenced-by-count":33,"title":["Standard\u2010dose efavirenz <i>vs.<\/i> standard\u2010dose nevirapine in antiretroviral regimens among HIV\u20101 and tuberculosis co\u2010infected patients who received rifampicin"],"prefix":"10.1111","volume":"9","author":[{"given":"W","family":"Manosuthi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Mankatitham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lueangniyomkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Chimsuntorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sungkanuparph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,7]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1194","article-title":"Impact of new antiretroviral combination therapies in HIV\u2010infected patients in Switzerland","volume":"315","author":"Egger M","year":"1997","journal-title":"prospective multicentre study. Swiss HIV Cohort Study"},{"key":"e_1_2_6_3_2","first-page":"863","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV\u20101 patients","volume":"353","author":"Ledergerber B","year":"1999","journal-title":"a prospective cohort study. Swiss HIV Cohort Study"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000230521.86964.86"},{"key":"e_1_2_6_6_2","first-page":"827","article-title":"Treatment for adult HIV infection","volume":"296","author":"Hammer SM","year":"2006","journal-title":"2006 recommendations of the International AIDS Society \u2013 USA Panel"},{"key":"e_1_2_6_7_2","first-page":"1253","article-title":"Comparison of first\u2010line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine","volume":"363","author":"Van Leth F","year":"2004","journal-title":"a randomised open-label trial, the 2NN Study"},{"issue":"1","key":"e_1_2_6_8_2","first-page":"63","article-title":"Complications of antiretroviral therapy in patients with tuberculosis","volume":"196","author":"McIlleron H","year":"2007","journal-title":"drug interactions, toxicity, and immune reconstitution inflammatory syndrome"},{"key":"e_1_2_6_9_2","first-page":"985","article-title":"Rifampin and rifabutin drug interactions","volume":"162","author":"Finch CK","year":"2002","journal-title":"an update"},{"key":"e_1_2_6_10_2","first-page":"231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox W","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3966-3969.2005"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/505210"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183630.27665.30"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912030-00029"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200112150-00007"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200303070-00024"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12020505"},{"issue":"1","key":"e_1_2_6_19_2","first-page":"5","article-title":"Tuberculosis and HIV infection","volume":"196","author":"Nunn P","year":"2007","journal-title":"the global setting"},{"issue":"1","key":"e_1_2_6_20_2","first-page":"1","article-title":"Update on HIV\/AIDS in Thailand","volume":"84","author":"Ruxrungtham K","year":"2001","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404150-00014"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/428093"},{"key":"e_1_2_6_23_2","first-page":"118","article-title":"High hepatotoxicity rate seen among HAART patients","volume":"16","author":"Reisler K.","year":"2001","journal-title":"AIDS Alert"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00005"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1258\/09564620360719840"},{"key":"e_1_2_6_26_2","first-page":"182","article-title":"Hepatotoxicity associated with nevirapine or efavirenz\u2010containing antiretroviral therapy","volume":"35","author":"Sulkowski MS","year":"2002","journal-title":"role of hepatitis C and B infections"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/518657"},{"key":"e_1_2_6_28_2","first-page":"623","article-title":"A review of efficacy studies of 6\u2010month short\u2010course therapy for tuberculosis among patients infected with human immunodeficiency virus","volume":"32","author":"El\u2010Sadr WM","year":"2001","journal-title":"differences in study outcomes"},{"key":"e_1_2_6_29_2","first-page":"1349","article-title":"Prevalence of hepatitis B virus and hepatitis C virus co\u2010infection with human immunodeficiency virus in Thai patients","volume":"87","author":"Sungkanuparph S","year":"2004","journal-title":"a tertiary-care-based study"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00563.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00563.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:55:00Z","timestamp":1696877700000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00563.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,7]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00563.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00563.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,7]]}}}